According to a study presented during the Academy of Managed Care Pharmacy’s Nexus conference, industry professionals are hesitant to put their full weight behind patient-reported outcomes (PRO) data.
The study, which was funded by pharmaceutical company Pfizer, included lengthy phone interviews with 13 managed care representatives and five oncologists between Nov. 14 and Nov. 28, 2016.
According to an AMCP report, most respondents indicated they were at least open to PRO data, but have mostly kept their distance.
“U.S. payers and oncologists identified a number of obstacles to more consistent payer use of PROs,” the study’s authors concluded.